RUMI Scientific os organized around changing the landscape of drug discovery through the firm's proprietary human stem cell technology that uses single-cell, time-lapse imaging and customized analytic tools to identify effective and cost competitive treatments for human genetic diseases. The firm's micropattern technology enables the self-organization of human embryonic stem cells generating a signature defined by geometry and size that is driven by processes that occur in vivo as the cells differentiate to give rise to different human cell types. It is known that many disease-causing mutations change the signature. Use of isogenic cell lines recapitulating mutations that are causal to human diseases can be applied to high-throughput screens to identify compounds that revert the disease signature back to normal. The technology allows a high-resolution evaluation of cellular behaviors comparatively between normal and disease state, providing an opportunity to perform “clinical trials on human micropatterns”.
